Composition for contraception
View Patent ↗A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17β-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
1. A combination product for oral contraception, comprising
(a) 23 or 24 dosage units, each containing an estrogen selected from
>2.0 to 6.0 mg of 17β-estradiol and
0.020 mg of ethinylestradiol;
and a gestagen selected from
0.25 to 0.30 mg of drospirenone and
0.1 to 0.2 mg of cyproterone acetate,
and
b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days.
2. A combination preparation for oral contraception according to claim 1 , wherein the estrogen is ethinylestradiol.
3. A combination preparation of claim 2 , wherein the gestagen is cyproterone acetate.
4. A combination preparation of claim 2 , wherein the gestagen is drospirenone.
5. A combination preparation according to claim 1 , wherein the estrogen is present in a dose of 20 μg of ethinylestradiol or an equivalent dose of 17β-estradiol and the gestagen is present in a dose equivalent to 75 μg of gestadene.
6. A combination preparation according to claim 1 , which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle.
7. A combination preparation according to claim 1 , which comprises 23 dosage units, each containing 20 μg of ethinylestradiol and a dose of cyproterone acetate or drospirenone equivalent to 75 μg of gestodene and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle.
8. A combination preparation of claim 1 , wherein the estrogen is 17β-estradiol.
9. A combination preparation of claim 8 , wherein the gestagen is cyproterone acetate.
10. A combination preparation of claim 8 , wherein the gestagen is drospirenone.
11. A method of inducing contraception in a female of reproductive age who has not yet reached premenopause, comprising administering to said female who is desirous of contraception a monophasic composition comprising an estrogen selected from
2.0 to 6.0 mg of 17β-estradiol and
0.015 to 0.020 mg of ethynylestradiol;
and a contraceptively effective amount of a gestagen,
wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
12. A method of claim 11 wherein the gestagen is norethisterone.
13. A method of claim 11 wherein the gestagen is drospirenone.
14. A method of claim 13 wherein the amount of drospirenone in said composition is 1-3 mg.
15. A method of inducing contraception in a female of reproductive age who has not yet reached premenopause, comprising administering to said female who is desirous of contraception a monophasic composition comprising 0.015 to 0.020 mg of ethynylestradiol and 1-3 mg of drospirenone, wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.
16. A method of claim 15 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg.
17. A method of claim 16 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle.